EMA Moves To Make Review Of Safety Variations More Efficient
A new working group at the European Medicines Agency aims to ensure the agency's Pharmacovigilance Risk Assessment Committee (PRAC) is involved in evaluating safety-related variations when needed. These applications were previously assessed by a different committee.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.